Platelet GP IIb-IIIa receptor antagonists in primary angioplasty: Back to the future

Drugs

Volumn 75, Issue 11, 2015, Pages 1229-1253

  De Luca, Giuseppe ^a   Savonitto, Stefano ^b   Van't Hof, Arnoud W J ^c   Suryapranata, Harry ^d  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c ISALA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HIRULOG; TIROFIBAN; FIBRINOGEN RECEPTOR;

ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; CORONARY REPERFUSION; DRUG EFFECT; DRUG TARGETING; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; INTRACORONARY DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NO REFLOW PHENOMENON; NONHUMAN; PROGNOSTIC ASSESSMENT; PROTEIN BINDING; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CORONARY ARTERY DISEASE; HEMORRHAGE; MYOCARDIAL INFARCTION; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY ARTERY DISEASE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 84938213944     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0425-7     Document Type: Article

References (251)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-50.
2. Topol EJ, Yadav JS. Recognition of the importance of embolisation in atherosclerotic vascular disease. Circulation. 2000;101:570-80.
3. De Luca G, Suryapranata H, Chiariello M. Prevention of distal embolisation in patients undergoing mechanical revascularisation for acute myocardial infarction. A review of current status. Thromb Haemost. 2006;96:700-10.
4. De Luca G, van't Hof AW, Ottervanger JP, et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J. 2005;150:557-62.
5. De Luca G, Gibson CM, Bellandi F, et al. Impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis. 2010;30:23-8.
6. Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2005;45:508-14.
7. De Luca G, Ernst N, van't Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J. 2006;151:1256-9.
8. Dangas G, Aymong ED, Mehran R, CADILLAC Investigators, et al. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol. 2004;94:983-8.
9. De Luca G, Dirksen MT, Spaulding C, DESERT cooperation, et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost. 2013;110:826-33.
10. Capozzolo C, Piscione F, De Luca G, et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001;53:464-73.
11. Suryapranata H, De Luca G, van't Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart. 2005;91:641-5.
12. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37-44.
13. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109:1704-6.
14. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009;158:e43-50.
15. Stone GW, Lansky AJ, Pocock SJ, HORIZONS-AMI Trial Investigators, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-59.
16. Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv. 2009;2:515-23.
17. Spaulding C, Henry P, Teiger E, TYPHOON Investigators, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093-104.
18. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133:213-22.
19. De Luca G, Valgimigli M, Spaulding C, et al. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009;28:200-10.
20. Wallace EL, Abdel-Latif A, Charnigo R, et al. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109:932-40.
21. De Luca G, Cassetti E, Marino P. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials. J Thromb Thrombolysis. 2009;27:365-78.
22. De Luca G, Dirksen MT, Spaulding C, Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172:611-21.
23. Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-94.
24. Räber L, Kelbæk H, Ostojic M, COMFORTABLE AMI Trial Investigators, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777-87.
25. Di Lorenzo E, Sauro R, Varricchio A, et al. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI Trial. JACC Cardiovasc Interv. 2014;7:849-56.
26. De Luca G, van't Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J. 2004;25:1009-13.
27. De Luca G, van't Hof AW, de Boer MJ, et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation. 2004;109:958-61.
28. De Luca G, Maas AC, Suryapranata H, et al. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J. 2005;150:1248-54.
29. Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002;39:591-7.
30. De Luca G, Suryapranata H, Ottervanger JP, et al. Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J. 2005;150:1185-9.
31. Sakuma T, Leong-Poi H, Fisher NG, et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. J Am Soc Echocardiogr. 2003;16:15-21.
32. Limbruno U, De Carlo M, Pistolesi S, et al. Distal embolisation during primary angioplasty: histopathologic features and predictability. Am Heart J. 2005;150:102-8.
33. Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and noreflow phenomenon. Chest. 2002;122:1322-32.
34. Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolisation during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol. 2003;92:728-32.
35. Claessen BE, Maehara A, Fahy M, et al. Plaque composition by intravascular ultrasound and distal embolisation after percutaneous coronary intervention. JACC Cardiovasc Imaging. 2012;5:S111-8.
36. Yunoki K, Naruko T, Inoue T, et al. Relationship of thrombus characteristics to the incidence of angiographically visible distal embolisation in patients with ST-segment elevation myocardial infarction treated with thrombus aspiration. JACC Cardiovasc Interv. 2013;6:377-85.
37. Stone GW, Webb J, Cox DA, Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063-72.
38. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolisation during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112-7.
39. Napodano M, Ramondo A, Tarantini G, et al. Predictors and time-related impact of distal embolisation during primary angioplasty. Eur Heart J. 2009;30:305-13.
40. Fokkema ML, Vlaar PJ, Svilaas T, et al. Incidence and clinical consequences of distal embolisation on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J. 2009;30:908-15.
41. De Luca G, Suryapranata H, de Boer MJ, et al. Impact of vessel size on distal embolisation, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for STsegment elevation myocardial infarction. J Thromb Thrombolysis. 2009;27:198-203.
42. De Luca G, Gibson CM, Huber K, et al. EGYPT Cooperation. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. Am Heart J. 2009;158:416-21.
43. De Luca G, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolisation, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis. 2009;207:181-5.
44. De Luca G, Sauro R, Varricchio A, et al. Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES. J Thromb Thrombolysis. 2010;30:133-41.
45. De Luca G, Dirksen MT, Spaulding C, DESERT cooperation, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care. 2013;36:1020-5.
46. De Luca G, Van't Hof AW, Huber K, et al. Impact of advanced age on myocardial perfusion, distal embolisation, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors. Heart Vessels. 2014;29:15-20.
47. De Luca G, Gibson CM, Gyöngyösi M, et al. Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis. 2010;30:342-6.
48. De Luca G, van't Hof AW, Huber K, EGYPT cooperation, et al. Impact of hypertension on distal embolisation, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2013;112:1083-6.
49. De Luca G, Gibson CM, Huber K, EGYPT cooperation, et al. Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. EuroIntervention. 2012;8:470-6.
50. Niccoli G. The challenge of microvascular obstruction after primary percutaneous coronary intervention. Curr Vasc Pharmacol. 2013;11:243-4.
51. Dreyer W, Michael L, West M. Neutrophil accumulation in ischemic canine myocardium: insights into the time course, distribution, and mechanism of localisation during early reperfusion. Circulation. 1991;84:400-11.
52. Brown KK, Henson PM, Maclouf J, et al. Neutrophil-platelet adhesion: relative roles of platelet P-selectin and neutrophil b2 (CD18) integrins. Am J Respir Cell Mol Biol. 1998;18:100-10.
53. Diacovo TG, Roth SJ, Buccola JM, et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the b2-integrin CD11b/CD18. Blood. 1996;88:146-57.
54. Sheikh S, Nash GB. Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Blood. 1996;87:5040-50.
55. Ma XL, Weyrich AS, Lefer DJ, et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation. 1993;88:649-58.
56. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial ischemia: role for CD18-dependent PMN localisation and PMNplatelet interactions. Am J Physiol. 1993;265(5 Pt 2):H1750-61.
57. Tomai F, Ribichini F, Ghini AS, et al. Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur Heart J. 2005;26:2099-105.
58. Schindler TH, Nitzsche EU, Olschewski M. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation. 2004;110:1069-75.
59. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:98-111.
60. Engler RL. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion. Am J Cardiol. 1989;63(-suppl):19E-23E.
61. Wilson RF, Lesser JF, Laxson DD, et al. Intense microvascular constriction after angioplasty of acute thrombotic arterial lesions. Lancet. 1989;1:807-11.
62. Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27(7):779-88 (Epub 2006 Mar 2).
63. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283(22):2941-7.
64. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109(10):1223-5.
65. Stone GW, Dixon SR, Grines CL, Cox DA, Webb JG, Brodie BR, Griffin JJ, Martin JL, Fahy M, Mehran R, Miller TD, Gibbons RJ, O'Neill WW. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol. 2007;100(9):1370-5.
66. De Luca G, Parodi G, Sciagrà R, Venditti F, Bellandi B, Vergara R, Migliorini A, Valenti R, Antoniucci D. Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty. Int J Cardiol. 2013;167(4):1508-13.
67. Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, Gibson CM, Stone GW. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). JACC Cardiovasc Interv. 2014;7(7):733-40.
68. Tarantini G, Cacciavillani L, Corbetti F, Ramondo A, Marra MP, Bacchiega E, Napodano M, Bilato C, Razzolini R, Iliceto S. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol. 2005;46(7):1229-35.
69. de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Haznedar D, Grothoff M, Gutberlet M, Schuler G, Thiele H. Time-dependency, predictors and clinical impact of infarct transmurality assessed by magnetic resonance imaging in patients with STelevation myocardial infarction reperfused by primary coronary percutaneous intervention. Clin Res Cardiol. 2012;101(3):191-200.
70. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-7.
71. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48:1339-45.
72. Christiaens L, Macchi L. Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact? Curr Vasc Pharmacol. 2007;5:293-301.
73. Pregowski J, Witkowski A, Sitkiewicz D. Significance of aspirin and clopidogrel resistance in patients undergoing percutaneous coronary interventions. Curr Vasc Pharmacol. 2007;5:135-40.
74. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-16.
75. Saw J, Steinhubl SR, Berger PB, Clopidogrel for the Reduction of Events During Observation Investigators, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003;108(8):921-4.
76. Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 2003;108(18):2195-7.
77. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004;109(11):1335-8.
78. Ojeifo O, Wiviott SD, Antman EM, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013;6(12):1275-81.
79. Collet JP, Hulot JS, Abtan J, DOSAPI investigators, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-57.
80. Depta JP, Lenzini PA, Lanfear DE, et al. Clinical outcomes associated with proton pump inhibitor use amongclopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2015;15(1):20-5.
81. Zou JJ, Chen SL, Tan J, et al. Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of theproton pump inhibitor. PLoS One. 2014;9(1):e84985. doi:10.1371/journal.pone.0084985.
82. Tsantes AE, Ikonomidis I, Papadakis I, et al. Impact of the proton pump inhibitors and CYP2C19∗2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb Res. 2013;132(2):e105-11.
83. Dunn SP, Steinhubl SR, Bauer D, et al. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc. 2013;2(1):e004564. doi:10.1161/JAHA.112.004564.
84. Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-74.
85. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57:1251-63.
86. Valgimigli M, Tebaldi M, Campo G, FABOLUS PRO Investigators, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5(3):268-77.
87. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-6.
88. Zeymer U, Mochmann HC, Mark B, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mgclopidogrel versus 60 mg prasugrel in patients with acute STsegment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). JACC Cardiovasc Interv. 2015;8(1 Pt B):147-54.
89. Ibrahim K, Christoph M, Schmeinck S, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2014;85(5):649-56.
90. Bjelland TW, Hjertner O, Klepstad P, et al. Clopidogrel does not work following cardiopulmonary resuscitation. Eur J Clin Pharmacol. 2013;69(9):1727-32.
91. Součková L, Opatřilová R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69(3):309-17.
92. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63:630-5.
93. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8(1). doi:10.1161/CIRCINTERVENTIONS.114.001593.
94. Montalescot G, van 't Hof AW, Lapostolle F, ATLANTIC Investigators, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016-27.
95. Montalescot G, Sideris G, Meuleman C, ALBION Trial Investigators, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-8.
96. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930-42.
97. Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, Giurlani L, Gensini GF, Abbate R, Antoniucci D. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J. 2014;167:909-14.
98. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost. 2008;100:184-95.
99. Mikhailidis DP, Barradas MA, O'Donoghue S, et al. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets. 1990;1:189-92.
100. Greenbaum RA, Barradas MA, Mikhailidis DP, et al. Effect of heparin and contrast medium on platelet function during routine cardiac catheterisation. Cardiovasc Res. 1987;21:878-85.
101. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy. Circulation. 1999;99(1):E1-11.
102. Phillips DR, Charo IF, Prise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831-43.
103. Wagner C, Mascelli M, Neblock D, Weisman H, Coller B, Jordan R. Analysis of GP IIb-IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88(3):907-14.
104. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GP IIb-IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation. 1999;99(17):2231-8.
105. Duperray A, Troesch A, Berthier R, Chagnon E, Frachet P, Uzan G, et al. Biosynthesis and assembly of platelet GPIIb-IIIa in human megakaryocytes: evidence that assembly between pro GPIIb and GPIIIa is a prerequisite for expression of the complex on the cell surface. Blood. 1989;74(5):1603-11.
106. Thornton MA, Poncz M, Korostishevsky M, Yakobson E, Usher S, Seligsohn U, et al. The human platelet aIIb gene is not closely linked to its integrin partner b3. Blood. 1999;94(6):2039-47.
107. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombastenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-38.
108. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb-IIIa complex. J Clin Invest. 1985;76:101-8.
109. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb-IIIa receptors in cardiovascular medicine. N Eng J Med. 1995;332:1553-9.
110. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80(4A):11B-20B.
111. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E, TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2364-73.
112. Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J Am Coll Cardiol. 2010;56:463-9.
113. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L- 700,462), a selective nonpeptide platelet glycoprotein IIb-IIIa antagonist, is active in man. Circulation. 1993;88:1512-7.
114. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, Aggarwal A, Kabbani SS, DiBattiste PM. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol. 2003;91:334-6.
115. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv. 2004;61:179-84.
116. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/III and avb3 integrins. Circulation. 1998;98:1085-91.
117. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v) beta3 in vascular biology. Thromb Haemost. 1998;80:726-34.
118. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997;100:87-9.
119. Baron JH, Moiseevaa EP, de Bonoa DP, Abrams KR, Gershlick AH. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis. Cardivasc Res. 2000;48:464-72.
120. Stouffer GA, Hu Z, Sajid M, et al. β3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907-15.
121. Blindt R, Bosserhoff AK, Zeiffer U, Krott N, Hanrath P, vom Dahl J. Abciximab inhibits the migration and invasion of human coronary artery smooth muscle cells. J Mol Cell Cardiol. 2000;32:2195-2206.
122. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
123. ISAR-SWEET Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627-35.
124. The ERASER investigators. Acute platelet inhibition with abciximab does not reduce instent restenosis. Circulation. 1999;100:799-806.
125. EPILOG Investigators. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. The EPILOG Investigation. N Eng J Med. 1997;336:1689-96.
126. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-35.
127. Sakuma T, Sari I, Goodman CN, Lindner JR, Klibanov AL, Kaul S. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty. Cardiovasc Res. 2005;66:552-61.
128. Simpson PJ, Todd RF, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988;81:624-9.
129. Lefer DJ, Shandelya SM, Serrano CV, et al. Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation. 1993;88:1779-87.
130. Jerome SN, Smith CW, Korthuis RJ. CD18-dependent adherence reactions play an important role in the development of the no-reflow phenomenon. Am J Physiol. 1993;264:479-83.
131. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748-55.
132. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387-94.
133. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999;34:1420-6.
134. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1(CD11b/CD18, alphaMbeta2). Thromb Res. 2002;107:121-8.
135. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Biol. 1997;17:528-35.
136. Azar RR, Badaoui G, Sarkis A, et al. Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention. Clin Cardiol. 2010;33:14-9.
137. Walters DL, Ray MJ, Wood P, Perrin EJ, Bett JH, Aroney CN. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneuos intervention. Eur J Clin Invest. 2010;40:139-47.
138. Ercan E, Tenqiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. Am Heart J. 2004;147:54-7.
139. Ueland T, Aukrust P, Omdal TR, et al. Effect of eptifibatide on platelet-mediated inflammation in acute coronary syndromes. Int J Cardiol. 2011;151:385-7.
140. Mazaev AA, Naimushin YA, Masenko VP, Ruda MY, Mazurov AV. Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. J Thromb Thrombolysis. 2009;27:146-53.
141. Brener SJ, Ban LA, Burchenal JEB, On the behalf of the RAPPORT investigators, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-41.
142. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695-701.
143. Petronio AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003;24:67-76.
144. Stone G, Grines CL, Cox AD, For the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators, et al. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-66.
145. Montalescot G, Barragan P, Wittemberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-903.
146. Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J. 2002;143:334-41.
147. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90:533-6.
148. Lee CW, Moon DH, Hong MK, et al. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90:1243-6.
149. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005;150:1015-8.
150. Steen H, Lehrke S, Wiegand UK, et al. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J. 2005;149:564-7.
151. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:1187-93.
152. Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, Memisha G, Santoro GM. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109(14):1704-6.
153. Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, Van't Veer M, Koolen JJ, Pijls NH, Michels R. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. JACC Cardiovasc Interv. 2012;5(3):313-22.
154. Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schömig A, Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933-40.
155. Schulz S, Birkmeier KA, Ndrepepa G, Moshage W, Dotzer F, Huber K, Dirschinger J, Seyfarth M, Schömig A, Kastrati A, Mehilli J. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clin Res Cardiol. 2010;99:795-802.
156. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolisation during percutaneous revascularisation of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am J Cardiol. 1997;80:985-8.
157. Islam MA, Blankenship JC, Balog C, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ;EPISTENT Investigators. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol. 2002;90:916-21.
158. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-65.
159. De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularisation for STsegment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol. 2006;47:685-6.
160. De Luca G, Navarese E, Marino P. Risk profile and benefits from GP IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705-13.
161. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28(4):443-9.
162. De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost. 2005;93:820-3.
163. Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a metaanalysis of randomized trials. Can J Cardiol. 2011;27(5):548-54.
164. Mahmoudi M, Delhaye C, Wakabayashi K, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Interv Cardiol. 2011;24(4):351-6.
165. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularisation: The Task Force on Myocardial Revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.
166. Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Thromb Res. 2013;132:e36-41.
167. Lee CH, Ngo HM, Sewianto A, Nguyen TH, Lee J, Teo SG, Low AF, Tan HC. Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145:355-7.
168. Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Roy L, Déry JP, Courtis J, Nault I, Poirier P, Costerousse O, De Larochellière R. One-year clinical outcome after abciximab bolusonly compared with abciximabbolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study. Am Heart J. 2008;156:135-40.
169. Valgimigli M, Campo G, Tebaldi M, Monti M, Gambetti S, Scalone A, Parrinello G, Ferrari R, Fabolus Synchro (facilitation through abciximab by dropping infusion Line in patients undergoing coronary stenting. Synergy with clopidogrel at high loading dose regimen) Investigators. Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. J Thromb Haemost. 2010;8:1903-11.
170. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv. 2004;62:186-92.
171. Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a metaanalysis of randomized trials. Platelets. 2012;23:274-81.
172. Desch S, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial. J Am Coll Cardiol. 2013;62:1214-5.
173. Eitel I, Wöhrle J, Suenkel H, et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol. 2013;61:1447-54.
174. De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a metaanalysis of 8 randomized trials. Atherosclerosis. 2012;222:426-33.
175. Stone GW, Maehara A, Witzenbichler B, INFUSE-AMI Investigators, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817-26.
176. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109-17.
177. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R, Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA. 2008;299:1788-99.
178. Marzocchi A, Manari A, Piovaccari G, Marrozzini C, Marra S, Magnavacchi P, Sangiorgio P, Marinucci L, Taglieri N, Gordini G, Binetti N, Guiducci V, Franco N, Reggiani ML, Saia F, FATA Investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofibanor abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J. 2008;29:2972-80.
179. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004;94(1):35-9.
180. Raveendran G, Ting HH, Best PJ, Holmes DR Jr, Lennon RJ, Singh M, Bell MR, Long KH, Rihal CS. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc. 2007;82(2):196-202.
181. Akerblom A, James SK, Koutouzis M, Lagerqvist B, Stenestrand U, Svennblad B, Oldgren J. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography andAngioplasty Registry). J Am Coll Cardiol. 2010;56(6):470-5.
182. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O'Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M, Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008;51(5):529-35.
183. Austin D, Mackay DF, Morley R, Christie J, Hennigan B, de Belder MA, Pell JP, Oldroyd KG. High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study. EuroIntervention. 2015;10:1187-94.
184. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668-73.
185. Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M. Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 2010;106(2):167-174.e1.
186. Weitz JI. Biological rationale for the therapeutic role of specific antithrombins. Coron Artery Dis. 1996;7:409-19.
187. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-91.
188. Nowak G, Schrör K. Hirudin-the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece. Thromb Haemost. 2007;98:116-9.
189. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993-1003.
190. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (Lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol. 1999;34:966-73.
191. Jang IK, Brown DF, Giugliano RP, et al. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999;33:1879-85.
192. Theroux P, Perez-Villa F, Waters D, et al. Randomized doubleblind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 1995;91:2132-9.
193. White HD, Aylward PE, Frey MJ, et al. Randomized, doubleblind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997;96:2155-61.
194. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 6 trial. Am J Cardiol. 1995;75:7-13.
195. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-7.
196. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-30.
197. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Circulation. 1994;90:1638-42.
198. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-82.
199. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-21.
200. White HD. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Hirulog and Early Reperfusion or Occlusion (HERO) Study Group. Lancet. 2001;358:1855-63.
201. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost. 2009;102:428-36.
202. Stone GW, Witzenbichler B, Guagliumi G, HORIZONS-AMI Trial Investigators, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-30.
203. Stone GW, Witzenbichler B, Guagliumi G, HORIZONS-AMI Trial Investigators, et al. Heparin plus a glycoprotein IIb-IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-204.
204. Shahzad A, Kemp I, Mars C, For the HEAT-PPCI trial investigators, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014. doi:10.1016/S0140-6736(14)60924-7 [Epub ahead of print].
205. Steg PG, van 't Hof A, Hamm CW, EUROMAX Investigators, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369:2207-17.
206. Han Y, Guo J, Zheng Y, BRIGHT Investigators, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313:1336-46.
207. Dangas GD, Caixeta A, Mehran R, Harmonizing Outcomes With Revascularisation and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123:1745-56.
208. De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol. 2013;168(3):2070-81.
209. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol. 2012;60(24):2481-9.
210. Valgimigli M, Gagnor A, Calabró P, MATRIX Investigators, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015. doi:10.1016/S0140-6736(15)60292-6 [Epub ahead of print].
211. De Luca G, Parodi G, Antoniucci D. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis. J Thromb Thrombolysis. 2010;30:452-8.
212. Parodi G, De Luca G, Moschi G, et al. Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis. 2010;30:446-51.
213. Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, Grip L, Albertsson P. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart. 2011;97:1484-8.
214. Hibbert B, MacDougall A, Labinaz M, O'Brien ER, So DY, Dick A, Glover C, Froeschl M, Marquis JF, Wells GA, Blondeau M, Le May MR. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv. 2012;5:805-12.
215. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384:599-606.
216. Navarese EP, Schulze V, Andreotti F, et al. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb-IIIa inhibitors in patients with acute coronary syndrome. JACC Cardiovasc Interv. 2015;8(1 Pt B):201-13. doi:10.1016/j.jcin.2014.10.003.
217. Valgimigli M, Calabrò P, Cortese B, MATRIX investigators, et al. Scientific foundation and possible implications for practice of the minimizing adverse haemorrhagic events by transradial access site and systemic implementation of angiox (MATRIX) trial. J Cardiovasc Transl Res. 2014;7:101-11.
218. De Luca G, Ernst N, Zijlstra F, van 't Hof AW, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, Suryapranata H. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2004;43:1363-7.
219. Dudek D, Dziewierz A, Siudak Z, Rakowski T, Zalewski J, Legutko J, Mielecki W, Janion M, Bartus S, Kuta M, Rzeszutko L, De Luca G, Zmudka K, Dubiel JS. Transportation with very long transfer delays (>90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction: the Krakow Network. Int J Cardiol. 2010;139:218-27.
220. De Luca G, Ernst N, Suryapranata H, et al. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty. Am J Cardiol. 2005;95:1361-3.
221. van't Hof AW, Ernst N, de Boer MJ, On-TIME study group, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J. 2004;25: 837-46.
222. Gibson CM, Kirtane AJ, Murphy SA, TIMI Study Group, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J. 2006;152:668-75.
223. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517-24.
224. Gabriel HM, Oliveira JA, da Silva PC, et al. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv. 2006;68:218-24.
225. Gyongyosi M, Domanovits H, Benzer W, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalisation of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multicentre randomized ReoPro-BRIDGING Study. Eur Heart J. 2004;25:2125-33.
226. Rakowski T, Zalewski J, Legutko J, et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J. 2007;153:360-5.
227. Petronio AS, De Carlo M, Strata E, Gistri R, Palmieri C, Aquaro G, Borelli G, Vaghetti M, Delle Donne M, Lombardi M, Berti S. Impact of early abciximab administration on infarct size in patients with ST-elevation myocardial infarction. Int J Cardiol. 2012;155:230-5.
228. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart. 2008;94:1548-58.
229. De Luca G, Michael Gibson C, et al. Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. J Thromb Thrombolysis. 2009;28:288-98.
230. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9:2361-70.
231. Van't Hof AW, Ten Berg J, Heestermans T, Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537-46.
232. Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van't Hof AW. High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial. Heart. 2011;97:106-11.
233. ten Berg JM, van 't Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C, On-TIME 2 Study Group. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446-55.
234. Dudek D, Siudak Z, Janzon M, EUROTRANSFER Registry Investigators, et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab - EUROTRANSFER Registry. Am Heart J. 2008;156:1147-54.
235. Ortolani P, Marzocchi A, Marrozzini C, et al. Long-term effectiveness of early administration of glycoprotein IIb-IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30:33-43.
236. Huber K, Holmes DR Jr, van't Hof AW, et al. Use of glycoprotein IIb-IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J. 2010;31:1708-16.
237. Le May MR, Wells GA, Glover CA, So DY, Froeschl M, Marquis JF, O'Brien ER, Turek M, Thomas A, Kass M, Jadhav S, Labinaz M. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Interv. 2009;2:330-8.
238. Ellis SG, Tendera M, de Belder MA, FINESSE Investigators, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205-17.
239. Herrmann HC, Lu J, Brodie BR, FINESSE Investigators, et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv. 2009;2:917-24.
240. Ellis SG, Tendera M, de Belder MA, FINESSE Investigators, et al. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2:909-16.
241. Heestermans T, van't Hof AW, ten Berg JM, van Werkum JW, Boersma E, Mosterd A, Stella PR, van Zoelen AB, Gosselink AT, Kochman W, Dill T, Koopmans PC, van Houwelingen G, Zijlstra F, Hamm C. The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J. 2010;160:1079-84.
242. Heestermans T, de Boer MJ, van Werkum JW, Mosterd A, Gosselink AT, Dambrink JH, van Houwelingen G, Koopmans P, Hamm C, Zijlstra F, ten Berg JM, van't Hof AW. Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay. EuroIntervention 2011;7:442-8.
243. Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, Cayla G, Pena A, Brugier D, Barthelemy O, Montalescot G, Weisel JW. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011;57:1359-67.
244. Sadowski M, Zabczyk M, Undas A. Coronary thrombus composition: links with inflammation, platelet and endothelial markers. Atherosclerosis. 2014;237(2):555-61. doi:10.1016/j.atherosclerosis.2014.10.020 (Epub 2014 Oct 18).
245. Ramaiola I, Padró T, Peña E, Juan-Babot O, Cubedo J, Martin-Yuste V, Sabate M, Badimon L. Changes in thrombus composition and profilin-1 release in acute myocardial infarction. Eur Heart J. 2015;36:965-75.
246. Montalescot G, van't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW, ATLANTIC Investigators. Prehospital ticagrelor in STsegment elevation myocardial infarction. N Engl J Med. 2014;371:1016-27.
247. Huber K, Gersh BJ, Goldstein P, Granger CB, Armstrong PW. The organisation, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. Eur Heart J. 2014;35:1526-32.
248. Quinn T, Johnsen S, Gale CP, Snooks H, McLean S, Woollard M, Weston C, Myocardial Ischaemia National Audit Project (MINAP) Steering Group. Effects of prehospital 12-lead ECG on processes of care and mortality in acute coronary syndrome: a linked cohort study from the Myocardial Ischaemia National Audit Project. Heart. 2014;100:944-50.
249. Schoos MM, Sejersten M, Hvelplund A, Madsen M, Lønborg J, Steinmetz J, Treschow PM, Pedersen F, Jørgensen E, Grande P, Kelbæk H, Clemmensen P. Reperfusion delay in patients treated with primary percutaneous coronary intervention: insight from a real world Danish ST-segment elevation myocardial infarction population in the era of telemedicine. Eur Heart J Acute Cardiovasc Care. 2012;1:200-9.
250. Birkemeyer R, Rillig A, Treusch F, Koch A, Miljak T, Meyerfeldt U, Kunze M, Jung W, Höher M. Abortion of myocardial infarction by primary angioplasty mainly depends on preprocedural TIMI flow. EuroIntervention. 2011;6:854-9.
251. Lamfers EJ, Hooghoudt TE, Hertzberger DP, Schut A, Stolwijk PW, Verheugt FW. Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients' characteristics, and prognosis. Heart. 2003;89:496-501.